Gómez-Almaguer D, Ruiz-Argüelles GJ, Gutiérrez ACH, Jaime-Pérez JC

Idioma: Español
Referencias bibliográficas: 41
Paginas: 291-297
Archivo PDF: 63.76 Kb.

RESUMEN

El trasplante alogénico no mieloablativo basa su efecto en la capacidad de los linfocitos del donador de erradicar a la enfermedad residual del paciente. El empleo de dosis reducidas de intensidad de radioterapia y/o quimioterapia permite su empleo en pacientes de edad avanzada y aún con comorbilidad. La poca toxicidad del procedimiento evita frecuentemente la hospitalización del paciente, se asocia a menor frecuencia de infecciones y de transfusiones, por ello el costo es sensiblemente menor e ideal para países pobres. Se ha utilizado con éxito desde hace ocho años y en nuestro país su aplicación es cada vez más frecuente. La utilidad principal se ha observado en leucemias crónicas y linfomas indolentes. En leucemia aguda mieloblástica en primera remisión también es útil, siendo menos efectivo en la leucemia aguda linfoblástica y los linfomas no-Hodgkin agresivos. También puede ser utilizado en niños y en pacientes con enfermedades benignas. El trasplante no-mieloablativo es una realidad en el área de los trasplantes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Storb R. Non-myeloablative allogeneic transplantation state of the art. Pediatr Transpl 2004; 8: 12-18.

2. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1998; 6: 1562-8.

3. Weiden PL, Fluornoy N, Thomas ED, et al. Antileukemic effect of graft versus host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979; 300: 1068–73.

4. Horowitz MM, Gale RP, Sondel PM, et al. Graft versus leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-62.

5. Weissman IL. Stem cells: units of development, units of regeneration and units in evolution. Cell 2000; 100: 157-68.

6. Weissman IL. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 2000; 287: 1442-6.

7. Childs R, Barrett J. Non-myeloablative allogeneic immunotherapy for solid tumors. Annu Rev Med 2004; 55: 459-75.

8. Slavin S. Reduced intensity conditioning or non-myeloablative stem transplantation: introduction, rationale and historic background. Semin Oncol 2004; 31: 1-3.

9. Saito T, Kanda Y, Kami, et al. Therapeutic potential of a reduced intensity preparative regimen for allogeneic transplantation with cladribine, busulfan and antithymocyte globulin against advanced/refractory leukemia/lymphoma. Clin Cancer Res 2002; 8:1014-20.

10. Childs R, Barrett J. Non-myeloablative allogeneic immunotherapy for solid tumors. Annu Rev Med 2004; 55: 459-75.

11. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-41.

12. Slavin S, Nagler A, Naprastek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematological diseases. Blood 1998; 91: 756-63.

13. Chakraverty R, Peggs K, Chapra R, et al. Limiting transplantation related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen. Blood 2002; 99:1071-8.

14. Sandmaier BM, Maloney DG, Gooley TA et al. Low dose TBI conditioning for hematopoietic stem cell transplant (HSCT) from HLA-matched related donors for patients with hematological malignancies: influence of fludarabine or cytoreductive autografts on outcome. Blood 2002; 100: 145.

15. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematological malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-7.

16. Ruiz-Argüelles G, Gómez-Almaguer D. Breaking dogmata to help patients: non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004; 4: 1693-9.

17. Nusair S, Breuer R, Shapira M, et al. Low incidence of pulmonary complications following non-myeloablative stem cell transplantation. Eur Respir J 2004; 23: 440-5.

18. Diaconesu R, Flowers C, Storer B, et al. Morbidity and mortality with non-myeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-8.

19. Junghans C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following non-myeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Blood 2002; 99: 1978-85.

20. Junghans C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following non-myeloablative compared with myeloablative allogeneic stem cell transplantation: a matched control study. Blood 2002; 99: 1978-85.

21. Weissinger F, Sandmaier BM, Maloney DG, et al. Decreased transfusion requirements for patients receiving non-myeloablative compared with conventional peripheral blood stem cell transplant from HLA-identical siblings. Blood 2001; 98: 3584-8.

22. Miel CM, Martin PJ, Leisenring W, et al. Graft versus host disease after non-myeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-62.

23. Bacigalupo A. Third EBMT/AMGEN workshop on reduced-intensity conditioning allogeneic hematopoietic stem cell transplants (RIC-HSCT) and panel consensus. Bone Marrow Transpl 2004; 33: 691-6.

24. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer Leukemia Group B. N Engl J Med 1994; 331: 896-903.

25. Appelbaum FR, Clift RA, Buckner CD, et al. Allogeneic marrow transplantation for acute non-lymphoblastic leukemia after first relapse. Blood 1983; 61: 949-53.

26. Neiderwiser D, Maris M, Shizuru JA, et al. Low dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosupression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-9.

27. Malladi RK, Peniket AJ, Norton AE, et al. Favorable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. Eur J Haematol 2004; 73: 85-92.

28. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematological malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-400.

29. Hoelzer D, Thiel H, Loffler H et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123-31.

30. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.

31. Keating M, O‘Brien S, Lerner S, et al. Combination chemo-antibody therapy with fludarabine, cyclophosphamide, and rituximab achieves high CR rate in previously untreated chronic lymphocytic leukemia. Blood 2000; 96: 514.

32. Khouri, Lee M, Saliba R. Non-ablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation on survival. Experimental hematology 2004; 32: 28-35.

33. Van Beisen K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood 1998; 92: 1832-6.

34. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin‘s disease. J Clin Oncol 1996; 14: 572-8.

35. Lalancette M, Rezvani K, Szydlo , et al. Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience. Blood 2000; 96: 204a.

36. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000; 25: 131-3.

37. Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transpl 2003; 9: 157-61.

38. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Rangel JD et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: a prospective study. Leuk Lymphoma 2004; 45: 1191-5.

39. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Morales E. Trasplante de células progenitoras hematopoyéticas. En: Góngora-Biachi R. (editor) Hematología: actualización 2004. Mérida, México: Ediciones de la Agrupación Mexicana para el Estudio de la Hematología A. C.; 2004, p. 139-48.

40. Sosa-Sánchez R, Córdova MS, Labardini JR, Chávez-Peón F. Trasplante de médula ósea en anemia aplástica. Reporte del primer caso en México. Rev Invest Clín Méx 1980; 32: 49-55.

41. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Rangel JD, Vela Ojeda J, Karduss A, Cantú-Rodríguez OG, Jaime-Pérez JC, et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with myeloid leukemia: results of a prospective study of the Latin American Cooperative Onco Hematology Group (LACOGH). Blood 2004; 104 (Suppl 1): 373b.